(43) International Publication Date 18 August 2005 (18.08.2005)

PCT

(10) International Publication Number WO 2005/075440 A1

(51) International Patent Classification⁷: C07D 239/42, 405/12, A61K 31/506, A61P 37/04, 29/00, 19/02, 19/10

(21) International Application Number:

PCT/GB2005/000341

(22) International Filing Date: 1 February 2005 (01.02.2005)

(25) Filling Language:

English

(26) Publication Language:

English

(30) Priority Data: 0402356.0

3 February 2004 (03.02.2004) GF

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): EATHERTON, Andrew, John [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). GIBLIN, Gerard, Martin, Paul [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). MITCHELL, William, Leonard [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). NAYLOR, Alan [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). RAWLINGS, Derek, Anthony [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). WALL, Ian, David [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB).
- (74) Agent: WALKER, Ralph, Francis; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EB, BG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, L\$, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR. HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW. ML, MR, NE. SN, TD, TG)

[Continued on next page]

(54) Title: 2- (PHENYLAMINO) -PYRIMIDIN-5-AMIDES AS CANNABINOID 2 RECEPTORS MODULATORS FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS

$$R'R^2N \xrightarrow{N} N$$

$$R^6$$

$$(1)$$

(57) Abstract: The present invention relates to novel pyrimidine derivatives such as compounds of formula (I), and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.

A1

2005/075440